U.S was the largest of Charles River Laboratories International, Inc.’s 5 reported lines in fiscal 2025, at $2.14B — 53% of $4.02B.
| Geography | FY 2010 | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $2.34B | $2.35B | $2.24B | $2.14B | |||||||||
| Europe | $1.03B | $1.08B | $1.08B | $1.10B | |||||||||
| Canada | $398.98M | $487.31M | $482.09M | $501.03M | |||||||||
| Asia Pacific | $192.84M | $200.83M | $196.95M | $205.02M | |||||||||
| Japan | — | — | — | — | |||||||||
| Other Non-U.S | — | — | — | — | |||||||||
| Other | $9.96M | $16.85M | $52.82M | $64.87M | |||||||||
| Total | $3.98B | $4.13B | $4.05B | $4.02B |
In fiscal 2025, which ended December 27, 2025, the 5 regions Charles River Laboratories International, Inc. reported in this breakdown added up to $4.02B. That was down 0.9% from $4.05B in fiscal 2024. U.S was the largest region, at $2.14B or 53.3% of the total, followed by Europe ($1.10B, 27.5%) and Canada ($501.03M, 12.5%). Together, the two largest regions made up 80.8% of this total.
Compared with fiscal 2024, Asia Pacific grew the fastest, rising 4.1% to $205.02M. U.S fell the most, down 4.4% to $2.14B. Over fiscal 2022 to 2025, revenue across these regions went from $3.98B to $4.02B, a compound annual growth rate of 0.3%. U.S's share of the total fell from 58.9% to 53.3% over the same years.
The table also keeps 2 regions that Charles River Laboratories International, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 13 fiscal years between 2010 and 2025, as reported in Charles River Laboratories International, Inc.'s annual filings.
Dsa was the largest of Charles River Laboratories International, Inc.’s 3 reported lines in fiscal 2025, at $2.40B — 74% of $3.24B.
| Timing of Transfer of Good or Service | FY 2010 | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dsa | $2.44B | $2.61B | $2.45B | $2.40B | |||||||||
| Discovery & Safety Assessment | — | — | — | — | |||||||||
| Research Models & Services | — | — | — | — | |||||||||
| Preclinical Services | — | — | — | — | |||||||||
| Rms | $398.47M | $414.40M | $448.48M | $456.99M | |||||||||
| Manufacturing Support | — | — | — | — | |||||||||
| Manufacturing | $418.07M | $381.94M | $407.47M | $383.68M | |||||||||
| Other Manufacturing Support | — | — | — | — | |||||||||
| Emd | — | — | — | — | |||||||||
| Total | $3.26B | $3.41B | $3.30B | $3.24B |
In fiscal 2025, which ended December 27, 2025, the 3 revenue lines Charles River Laboratories International, Inc. reported in this breakdown added up to $3.24B. That is less than the $4.02B in its breakdown by region, so these revenue lines do not account for all of its revenue that year. Dsa was the largest revenue line, at $2.40B or 74.1% of the total, followed by Rms ($456.99M, 14.1%) and Manufacturing ($383.68M, 11.8%). Together, the two largest revenue lines made up 88.2% of this total.
Compared with fiscal 2024, Rms grew the fastest, rising 1.9% to $456.99M. Manufacturing fell the most, down 5.8% to $383.68M.
The table also keeps 6 revenue lines that Charles River Laboratories International, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 13 fiscal years between 2010 and 2025, as reported in Charles River Laboratories International, Inc.'s annual filings.
Service was the largest of Charles River Laboratories International, Inc.’s 2 reported lines in fiscal 2025, at $3.25B — 81% of $4.02B.
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Service | $3.22B | $3.44B | $3.30B | $3.25B | ||||||
| Cost Of Services Provided (Excluding Amortization Of Intangible Assets) | — | — | — | — | ||||||
| Product | $759.16M | $689.39M | $745.85M | $765.28M | ||||||
| Cost Of Products Sold (Excluding Amortization Of Intangible Assets) | — | — | — | — | ||||||
| Total | $3.98B | $4.13B | $4.05B | $4.02B |
In fiscal 2025, which ended December 27, 2025, the 2 revenue lines Charles River Laboratories International, Inc. reported in this breakdown added up to $4.02B. That was down 0.9% from $4.05B in fiscal 2024. Service was the largest revenue line, at $3.25B or 80.9% of the total, followed by Product ($765.28M, 19.1%).
Compared with fiscal 2024, Product grew the fastest, rising 2.6% to $765.28M. Service fell the most, down 1.6% to $3.25B. Over fiscal 2022 to 2025, revenue across these revenue lines went from $3.98B to $4.02B, a compound annual growth rate of 0.3%. Service held a steady share of about 80.9%.
The table also keeps 2 revenue lines that Charles River Laboratories International, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Charles River Laboratories International, Inc.'s annual filings.
Charles River Laboratories International, Inc. (CRL) breaks its revenue down by region and revenue line. In fiscal 2025, its largest region was U.S, with $2.14B or 53.3% of the total, followed by Europe at $1.10B (27.5%).
U.S was Charles River Laboratories International, Inc.'s largest region in fiscal 2025, with $2.14B in revenue, 53.3% of the $4.02B reported across its 5 regions.
Dsa was Charles River Laboratories International, Inc.'s largest revenue line in fiscal 2025, with $2.40B in revenue, 74.1% of the $3.24B reported across its 3 revenue lines.
Of the Charles River Laboratories International, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Asia Pacific grew the fastest, rising 4.1% from $196.95M to $205.02M.
Every figure is taken from Charles River Laboratories International, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2010 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.